To report on the pause of clinical trials for CD19-directed CAR T therapies by Novartis and Bristol Myers Squibb due to safety concerns.
Approach:
Method: N
Method: o
Method: v
Method: a
Method: r
Method: t
Method: i
Method: s
Method: p
Method: u
Method: e
Method: d
Method: g
Method: h
Method: f
Method: c
Method: b
Method: l
Method: (
Method: 2
Method: 4
Method: m
Method: y
Method: w
Key Findings:
Three patients in Novartis trials died from IEC-HS, prompting a halt in studies, as confirmed by the company.
Bristol Myers Squibb observed transient and reversible inflammatory events in zola-cel trials, leading to a precautionary pause.
Interpretation:
IEC-HS is a known risk associated with CAR T therapies, and both companies are reviewing safety data with independent boards and health authorities.
Limitations:
The full extent of the safety concerns and the impact on ongoing trials is still under review, including the review of cases by independent safety boards and health authorities.
Conclusion:
Both companies are monitoring patients already treated and aim to resume trials after completing their safety reviews.
Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.
